Jasper Therapeutics Secures Health Canada Clearance for Briquilimab Clinical Trial in Asthma
Briquilimab: A Novel Approach to Asthma
Briquilimab is a new antibody therapy designed specifically to target asthma. This innovative approach aims to provide relief for patients struggling with this chronic condition. With Health Canada’s clearance, Jasper Therapeutics can now advance into clinical trials.
Health Canada Clearance
On September 10, 2024, Jasper Therapeutics (Nasdaq: JSPR) announced that it received the necessary clearance from Health Canada for its Phase 1b/2a clinical trial application. This critical step paves the way for ongoing research and development to better understand the efficacy of briquilimab in asthma treatment.
- Target: c-Kit receptor
- Phase 1b/2a study focused on safety and efficacy
- Aimed at providing effective asthma management
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.